The high identity of the Trypanosoma cruziGroup‐I of trans‐sialidases points them as promising vaccine immunogens

Abstract

Trans‐sialidase (TS) superfamily of proteins comprises eight subgroups, being the proteins of Group‐I (TS‐GI) promising immunogens in vaccine approaches against Trypanosoma cruzi. Strikingly, TS‐GI antigenic variability among parasite lineages and their influence on vaccine development has not been previously analyzed. Here, a search in GenBank detects 49 TS‐GI indexed sequences, whereas the main infecting human different parasite discrete typing units (DTU) are represented. In silico comparison among these sequences indicate that they share an identity above 92%. Moreover, the antigenic regions (T‐cell and B‐cell epitopes) are conserved in most sequences or present amino acid substitutions that scarcely may alter the antigenicity. Additionally, since the generic term TS is usually used to refer to different immunogens of this broad family, a further in silico analysis of the TS‐GI‐derived fragments tested in preclinical vaccines was done to determine the coverage and identity among them, showing that overall amino acid identity of vaccine immunogens is high, but the segment coverage varies widely. Accordingly, strong H‐2K, H‐2I, and B‐cell epitopes are dissimilarly represented among vaccine TS‐derived fragments depending on the extension of the TG‐GI sequence used. Moreover, bioinformatic analysis detected a set of 150 T‐cell strong epitopes among the DTU‐indexed sequences that strongly bind human HLA‐I supertypes. In all currently reported experimental vaccines based on TS‐GI fragments, mapping these 150 epitopes showed that they are moderately represented. However, despite vaccine epitopes do not present all the substitutions observed in the DTUs, these regions of the proteins are equally recognized by the same HLAs. Interestingly, the predictions regarding global and South American population coverage estimated in these 150 epitopes are similar to the estimations in experimental vaccines when the complete sequence of TS‐GI is used as an antigen. In silico prediction also shows that a number of these MHC‐I restricted T‐cell strong epitopes could be also cross‐recognized by HLA‐I supertypes and H‐2Kb or H‐2Kd backgrounds, indicating that these mice may be used to improve and facilitate the development of new TS‐based vaccines and suggesting an immunogenic and protective potential in humans. Further molecular docking analyses were performed to strengthen these results. Taken together, different strategies that would cover more or eventually fully of these T‐cell and also B‐cell epitopes to reach a high level of coverage are considered.